923032-37-5 | Refametinib

Packsize	Purity	Availability	Price	Discounted Price
1mg	95%	in stock	$29.00	$20.00
5mg	95%	in stock	$59.00	$41.00
10mg	95%	in stock	$83.00	$58.00
50mg	95%	in stock	$163.00	$114.00
100mg	95%	in stock	$270.00	$189.00

Description

• Catalog Number: AH81744
• Chemical Name: Refametinib
• CAS Number: 923032-37-5
• Molecular Formula: C19H20F3IN2O5S
• Molecular Weight: 572.3372
• MDL Number: MFCD18633256
• SMILES: OC[C@H](CC1(CC1)S(=O)(=O)Nc1c(OC)cc(c(c1Nc1ccc(cc1F)I)F)F)O

Computed Properties

• Complexity: 711
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 10
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 9
• XLogP3: 2.8

Literature

• Identification of potent Yes1 kinase inhibitors using a library screening approach.

  Bioorganic & medicinal chemistry letters 20130801

• Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20130301

• MEK and the inhibitors: from bench to bedside.

  Journal of hematology & oncology 20130101

• Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.

  PloS one 20120101

• Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice.

  Science (New York, N.Y.) 20110415

• BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.

  International journal of cancer 20101215

• Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

  BMC cancer 20100101

• RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

  Cancer research 20090901